Renal Safety of Everolimus in Addition to Cyclosporine Microemulsion in Cardiac Transplant Recipients.
NCT00170794 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL
Last updated 2016-11-18
Summary
The purpose of the study is to determine the extent of cyclosporine microemulsion dose reduction required to maintain stable renal function in maintenance cardiac transplant recipients, after initiation of everolimus.
Conditions
- Cardiac Transplantation
Interventions
- DRUG
-
Everolimus (RAD001)
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Novartis · Novartis
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-09-30
- Primary Completion
- 2006-07-31
More Related Trials
-
This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus
NCT00531063 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
NCT00154284 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus in Combination With Cyclosporine Microemulsion in de Novo Renal Transplant Recipients
NCT01276457 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus and Low Dose CNI Compared With MMF and Full CNI Dose in Heart Transplanted Patients: One Year Follow up
NCT00596557 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics of Everolimus and Enteric-Coated Mycophenolatesodium Before and After Withdrawal of Cyclosporine in Renal Transplant Patients
NCT00443937 ·Status: COMPLETED ·Phase: PHASE4
-
A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients
NCT00862979 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Everolimus With Enteric-Coated Mycophenolate Sodium (EC-MPS) in a Cyclosporine Microemulsion-free Regimen Compared to Standard Therapy in de Novo Renal Transplant Patients
NCT00154310 ·Status: COMPLETED ·Phase: PHASE4
-
Feasibility and Safety of Early Switch to Everolimus From Cyclosporine in de Novo Renal Transplant Patients
NCT00464399 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of Early Conversion to Everolimus From Cyclosporine in de Novo Renal Transplant Recipients
NCT00634920 ·Status: COMPLETED ·Phase: PHASE4
-
A Twelve-month, Multicenter, Open-label, Randomized Study of the Safety, Tolerability and Efficacy of Everolimus With Basiliximab, Corticosteroids and Two Different Exposure Levels of Tacrolimus in de Novo Renal Transplant Recipients
NCT00369161 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy, Safety and Tolerability of Everolimus in Combination With Reduced Exposure Cyclosporine or Tacrolimus in Paediatric Liver Transplant Recipients.
NCT01598987 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of the Switch From Sirolimus to Everolimus in Stable Maintenance Renal Transplant Patients Receiving a Calcineurin Inhibitor Free Regimen
NCT00170820 ·Status: COMPLETED ·Phase: PHASE4
-
Study of the Effect of Everolimus Immunosuppressive Combination Therapies on Renal Function When Used as a Maintenance Treatment for Liver Transplant Patients.
NCT03596970 ·Status: WITHDRAWN ·Phase: PHASE3
-
Everolimus in de Novo Heart Transplant Recipients
NCT01017029 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection
NCT00300274 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Safety, Tolerability & Efficacy of Certican in de Novo Heart Transplant (Tx) Patients
NCT00098007 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Early Versus Delayed Administration of Everolimus in de Novo Renal Transplant Patients
NCT00154297 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
NCT00251004 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy of Everolimus in Reducing Total Native Kidney Volume in Polycystic Kidney Disease Transplanted Recipients
NCT02134899 ·Status: COMPLETED ·Phase: PHASE3
-
Safe Renal Function In Long Term Heart Transplanted Patients
NCT00505102 ·Status: UNKNOWN ·Phase: PHASE4
-
This is a 2-year Follow-up Study to Evaluate the Long-term Effects in Patients Who Completed the Study CRAD001A2307.
NCT00531440 ·Status: COMPLETED ·Phase: PHASE3
-
Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients
NCT01025817 ·Status: COMPLETED ·Phase: PHASE3
-
Everolimus in de Novo Kidney Transplant Recipients
NCT01410448 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Everolimus in Combination With Cyclosporine Microemulsion Versus Everolimus in Combination With Enteric-coated Mycophenolate Sodium (EC-MPS), in Adult Renal Transplant Patients in Maintenance.
NCT00425308 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of the Early Introduction of Everolimus (Certican®) With Low Dose of Cyclosporine in de Novo Kidney Recipients After 1 Month of Transplantation
NCT01706471 ·Status: COMPLETED ·Phase: PHASE4